Salivary IgA from the sublingual compartment as a novel noninvasive proxy for intestinal immune induction

A Aase, H Sommerfelt, L B Petersen, M Bolstad, R J Cox, N Langeland, A B Guttormsen, H Steinsland, S Skrede, P Brandtzaeg, A Aase, H Sommerfelt, L B Petersen, M Bolstad, R J Cox, N Langeland, A B Guttormsen, H Steinsland, S Skrede, P Brandtzaeg

Abstract

Whole-saliva IgA appears like an attractive noninvasive readout for intestinal immune induction after enteric infection or vaccination, but has failed to show consistent correlation with established invasive markers and IgA in feces or intestinal lavage. For reference, we measured antibodies in samples from 30 healthy volunteers who were orally infected with wild-type enterotoxigenic Escherichia coli. The response against these bacteria in serum, lavage, and lymphocyte supernatants (antibody-in-lymphocyte-supernatant, ALS) was compared with that in targeted parotid and sublingual/submandibular secretions. Strong correlation occurred between IgA antibody levels against the challenge bacteria in sublingual/submandibular secretions and in lavage (r=0.69, P<0.0001) and ALS (r=0.70, P<0.0001). In sublingual/submandibular secretions, 93% responded with more than a twofold increase in IgA antibodies against the challenge strain, whereas the corresponding response in parotid secretions was only 67% (P=0.039). With >twofold ALS as a reference, the sensitivity of a >twofold response for IgA in sublingual/submandibular secretion was 96%, whereas it was only 67% in the parotid fluid. To exclude that flow rate variations influenced the results, we used albumin as a marker. Our data suggested that IgA in sublingual/submandibular secretions, rather than whole saliva with its variable content of parotid fluid, is a preferential noninvasive proxy for intestinal immune induction.

References

    1. Vet Res. 2012 Oct 10;43:68
    1. Immunol Rev. 2005 Aug;206:32-63
    1. Arch Dis Child. 1992 Jun;67(6):724-7
    1. J Immunol. 1979 Oct;123(4):1705-8
    1. Int Arch Allergy Appl Immunol. 1984;75(1):38-43
    1. Clin Exp Immunol. 1991 Feb;83(2):203-9
    1. J Oral Pathol Med. 1989 Dec;18(10):578-81
    1. Immunol Invest. 1986 Jun;15(4):339-49
    1. Infect Immun. 1991 Mar;59(3):996-1001
    1. J Immunol. 1986 May 15;136(10):3631-5
    1. Infect Immun. 1999 Dec;67(12):6234-41
    1. Vaccine. 2006 May 1;24(18):3709-18
    1. Gut. 1991 Jan;32(1):29-35
    1. Science. 1975 Dec 19;190(4220):1206-9
    1. Clin Exp Immunol. 1995 Oct;102(1):210-6
    1. Scand J Haematol Suppl. 1970;12:3-83
    1. Gastroenterology. 2000 Nov;119(5):1253-66
    1. BMC Infect Dis. 2014 Sep 04;14:482
    1. Infect Immun. 2011 Feb;79(2):950-60
    1. J Bacteriol. 1968 Jul;96(1):242-9
    1. J Immunol. 2001 May 1;166(9):5522-9
    1. Clin Diagn Lab Immunol. 2001 May;8(3):482-8
    1. Ann N Y Acad Sci. 2007 Mar;1098:288-311
    1. J Oral Microbiol. 2013;5:null
    1. Nat Rev Immunol. 2014 Oct;14(10):667-85
    1. Blood. 2005 Jul 15;106(2):593-600
    1. Vaccine. 2009 Jul 16;27(33):4529-36
    1. Scand J Immunol. 2009 Dec;70(6):505-15
    1. Cell Immunol. 1981 Sep 1;63(1):203-9
    1. Mucosal Immunol. 2008 Jan;1(1):11-22
    1. Trends Immunol. 2003 Feb;24(2):55-8
    1. J Infect Dis. 1984 Jun;149(6):884-93
    1. J Immunol. 2015 Aug 15;195(4):1368-71
    1. J Immunol. 2000 Feb 1;164(3):1595-601
    1. Infect Immun. 2001 Jun;69(6):3611-7
    1. Infect Immun. 1992 May;60(5):2023-9
    1. Vaccine. 2003 May 16;21(17-18):2042-51
    1. Infect Immun. 1981 Sep;33(3):697-703
    1. Clin Vaccine Immunol. 2011 Aug;18(8):1269-74
    1. Eur J Immunol. 2010 Apr;40(4):976-85
    1. Arch Oral Biol. 1985;30(11-12):765-71
    1. Expert Rev Vaccines. 2012 Apr;11(4):495-507
    1. J Exp Med. 2012 Feb 13;209(2):365-77
    1. J Clin Microbiol. 1986 Aug;24(2):203-9
    1. Pediatr Res. 1997 Apr;41(4 Pt 1):554-9
    1. J Clin Invest. 1978 Mar;61(3):731-7
    1. Vaccine. 2011 Nov 3;29(47):8487-9
    1. Immunol Cell Biol. 1995 Oct;73(5):397-404
    1. Pediatr Infect Dis J. 1989 Feb;8(2):105-9

Source: PubMed

3
Suscribir